Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Work In Process (2023 - 2026)

Maxcyte has reported Work In Process over the past 3 years, most recently at $501000.0 for Q4 2025.

  • Quarterly Work In Process rose 85.56% to $501000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $501000.0 through Dec 2025, up 85.56% year-over-year, with the annual reading at $501000.0 for FY2025, 85.56% up from the prior year.
  • Work In Process was $501000.0 for Q4 2025 at Maxcyte, up from $400000.0 in the prior quarter.
  • Over five years, Work In Process peaked at $1.0 million in Q2 2023 and troughed at $101000.0 in Q2 2024.
  • The 3-year median for Work In Process is $368500.0 (2025), against an average of $445016.7.
  • Year-over-year, Work In Process plummeted 89.93% in 2024 and then surged 233.66% in 2025.
  • A 3-year view of Work In Process shows it stood at $558000.0 in 2023, then plummeted by 51.61% to $270000.0 in 2024, then skyrocketed by 85.56% to $501000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Work In Process are $501000.0 (Q4 2025), $400000.0 (Q3 2025), and $337000.0 (Q2 2025).